Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study

MT Newswires Live08-19

Monte Rosa Therapeutics (GLUE) said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases.

Initial results are due in Q1 2025, the company said.

Monte Rosa said the study will assess the safety, pharmacokinetics, and target degradation of MRT-6160, intended to potentially treat autoimmune and inflammatory conditions by degrading proteins difficult to target with conventional drugs.

Preclinical results have indicated "encouraging results" for MRT-6160 in models of rheumatoid arthritis and other autoimmune disorders, the company said.

The company plans to use the phase 1 data to advance proof-of-concept studies in conditions like ulcerative colitis and rheumatoid arthritis, according to Chief Executive Markus Warmuth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2460339450?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-19 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2460339450","market":"sh","top_or_hot":-1,"title":"Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> (GLUE) said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases.</p><p>Initial results are due in Q1 2025, the company said.</p><p>Monte Rosa said the study will assess the safety, pharmacokinetics, and target degradation of MRT-6160, intended to potentially treat autoimmune and inflammatory conditions by degrading proteins difficult to target with conventional drugs.</p><p>Preclinical results have indicated \"encouraging results\" for MRT-6160 in models of rheumatoid arthritis and other autoimmune disorders, the company said.</p><p>The company plans to use the phase 1 data to advance proof-of-concept studies in conditions like ulcerative colitis and rheumatoid arthritis, according to Chief Executive Markus Warmuth.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-19 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monte Rosa Therapeutics (GLUE) said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases....</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4230","symbol_name":"旅客陆运","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2460339450","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2460339450","pubTimestamp":1724070304,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Monte Rosa Therapeutics  said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases.Initial results are due in Q1 2025, the company said.Monte Rosa said the study will assess the safety, pharmacokinetics, and target degradation of MRT-6160, intended to potentially treat autoimmune and inflammatory conditions by degrading proteins difficult to target with conventional drugs.Preclinical results have indicated \"encouraging results\" for MRT-6160 in models of rheumatoid arthritis and other autoimmune disorders, the company said.The company plans to use the phase 1 data to advance proof-of-concept studies in conditions like ulcerative colitis and rheumatoid arthritis, according to Chief Executive Markus Warmuth.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4230":"旅客陆运","BK4139":"生物科技","MRT":"Marti Technologies Inc.","BK4539":"次新股","GLUE":"Monte Rosa Therapeutics"},"translate_title":"Monte Rosa Therapeutics对MRT-6160自身免疫研究的第一批参与者进行给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":1,"MRT":1},"content_text":"Monte Rosa Therapeutics (GLUE) said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases.Initial results are due in Q1 2025, the company said.Monte Rosa said the study will assess the safety, pharmacokinetics, and target degradation of MRT-6160, intended to potentially treat autoimmune and inflammatory conditions by degrading proteins difficult to target with conventional drugs.Preclinical results have indicated \"encouraging results\" for MRT-6160 in models of rheumatoid arthritis and other autoimmune disorders, the company said.The company plans to use the phase 1 data to advance proof-of-concept studies in conditions like ulcerative colitis and rheumatoid arthritis, according to Chief Executive Markus Warmuth.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460339450"}